Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04262856
Recruitment Status : Recruiting
First Posted : February 10, 2020
Last Update Posted : February 17, 2020
Sponsor:
Information provided by (Responsible Party):
Arcus Biosciences, Inc.

Brief Summary:
This Randomized Phase 2 Open-label Study will Evaluate the Safety and Efficacy of Zimberelimab (AB122) Monotherapy, AB154 in Combination with Zimberelimab, and AB154 in Combination with Zimberelimab and AB928 in Front-line, PD-L1 Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Nonsquamous Non Small Cell Lung Cancer Squamous Non Small Cell Lung Cancer Lung Cancer Drug: Zimberelimab Drug: AB154 Drug: AB928 Phase 2

Detailed Description:

This is an open-label Phase 2 study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutics across multiple treatment arms.

Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab, 2) zimberelimab + AB154 (anti-TIGIT antibody), 3) zimberelimab + AB154 + AB928 (dual adenosine receptor antagonist). Participants that progress on the zimberelimab monotherapy arm may cross-over to receive the third arm combination of zimberelimab + AB154 + AB928.

The primary objective of this clinial study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Actual Study Start Date : January 13, 2020
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : June 23, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Arm 1 (Zimberelimab Monotherapy)
Participants will receive zimberelimab monotherapy by IV infusion.
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclononal antibody
Other Name: AB122

Experimental: Arm 2 (AB154 and Zimberelimab Combination Therapy)
Participants will receive AB154 in combination with zimberelimab by IV infusion.
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclononal antibody
Other Name: AB122

Drug: AB154
AB154 is a humanized monoclonal antibody targeting human TIGIT

Experimental: Arm 3 (AB154, Zimberelimab, and AB928 Combination Therapy)
Participants will receive oral AB928 in combination with zimberelimab and AB154 by IV infusion
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclononal antibody
Other Name: AB122

Drug: AB154
AB154 is a humanized monoclonal antibody targeting human TIGIT

Drug: AB928
AB928 is an A2aR and A2bR antagonist




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: From randomization until death from any cause (up to approximately 3-5 years) ]
    ORR as assessed by RECIST v1.1

  2. Progression-free survival (PFS) [ Time Frame: From randomization until death from any cause (up to approximately 3-5 years) ]
    PFS as assessed by RECIST v1.1


Secondary Outcome Measures :
  1. Duration of response (DoR) [ Time Frame: From the date of first occurence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) ]
    DoR as assessed by RECIST v1.1

  2. Disease control rate (DCR) [ Time Frame: From the date of first occurence of a documented objective response to first documentation of disease progression on death from any cause, whichever occurs first (up to approximately 3-5 years) ]
    DCR as assessed by RECIST v1.1

  3. Adverse Events [ Time Frame: From Screening until up to 100 days after the last dose (approximately 2 years) ]
    The number and percentage of participants that experience an adverse event (AE)

  4. Pharmacodynamics of AB122 [ Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years). ]
    Plasma concentration of AB122

  5. Pharmacodynamics of AB154 [ Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years). ]
    Plasma concentration of AB154

  6. Pharmacodynamics of AB928 [ Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years). ]
    Plasma concentration of AB928

  7. Immunogenicity of AB122 [ Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years). ]
    Percentage of participants who develop treatment-emergent anti-drug antibodies to AB122

  8. Immunogenicity of AB154 [ Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years). ]
    Percentage of participants who develop treatment-emergent anti-drug antibodies to AB154



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female participants; age ≥ 18 years
  • Histologically confirmed squamous or nonsquamous, PD-L1 positive, NSCLC that is locally advanced or metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation expression
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Adequate organ and marrow function

Exclusion Criteria:

  • Use of any live vaccines against infectious diseases within 28 days of first dose
  • Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications
  • Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody or Hepatitis C qualitative RNA or human immunodeficiency virus-1 (HIV-1) antibody
  • Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04262856


Contacts
Layout table for location contacts
Contact: Medical Director 510-694-6220 clinicaltrialinquiry@arcusbio.com

Locations
Layout table for location information
United States, Washington
Summit Cancer Centers Recruiting
Spokane, Washington, United States, 99208
Contact: Monika Chaudhry         
Principal Investigator: Arvind Chaudhry, MD         
Sponsors and Collaborators
Arcus Biosciences, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Director Arcus Biosciences, Inc.

Layout table for additonal information
Responsible Party: Arcus Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04262856    
Other Study ID Numbers: AB154CSP0002
First Posted: February 10, 2020    Key Record Dates
Last Update Posted: February 17, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arcus Biosciences, Inc.:
Non Small Cell Lung Cancer
Lung Cancer
NSCLC
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms